Valnivudine

956483-02-6

497.58

DMSO : 50 mg/mL (100.49 mM; Need ultrasonic)

Anti-infection; Anti-infection

Valnivudine (FV-100 free base), a prodrug of CF-1743, is an orally active anti-herpes zoster (HZ) nucleoside analogue. CF-1743, a bicyclic nucleoside analog (BCNA), has highly specific antiviral activity against varicella-zoster virus (VZV). Valnivudine is rapidly and extensively converted to CF-1743 in vivo^[1][2]. In Vitro: In vitro cytotoxicity studies in normal human primary hepatocytes, keratinocytes, and rapidly dividing HepG2 cells, Valnivudine (FV-100 free base) demonstrates mean 50% cytotoxic concentration values of >10 uM^[2].
CF-1743 (compound 4f) has anti-varicella-zoster virus (VZV) activity in VZV OKA (EC₅₀=0.3 nM), VZV YS (EC₅₀=0.1 nM) in HEL cell^[3].